NSAIDs and oral cancer
This article was originally published in The Tan Sheet
Long-term use of NSAIDs was linked to reduced incidence of oral cancer, but also was associated with increased risk of death from cardiovascular disease, an online study published Oct. 7 by The Lancet finds. The nested case-control study analyzed data from the Norwegian Health Survey database and identified individuals with oral cancer out of the 9,241 participants who had an increased risk for oral cancer due to heavy smoking, Jon Sudbø, MD, Norwegian Radium Hospital, Oslo, Norway, et al., state. Matched controls were chosen from the heavy smokers who did not have cancer. "NSAID use for 15 or more years had the lowest and most highly significant hazard ratio [.30] for oral cancer," Sudbø et al. explain. However, the finding linking increases in death due to cardiovascular disease and long-term NSAID use "highlights the need for a careful risk-benefit analysis when the long-term use of NSAIDs is considered," the authors say...
You may also be interested in...
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.